ethyl 2-(4-bromophenyl)-3-hydroxypropanoate | 797756-92-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(4-bromophenyl)-3-hydroxypropanoate
• 英文别名: 3-Hydroxy-2-(4-bromophenyl)-propionic acid ethyl ester
• CAS: 797756-92-4
• 化学式: C₁₁H₁₃BrO₃
• 分子量: 273.126
• InChiKey: PMMRZKHXEAWVIL-UHFFFAOYSA-N

物化性质

• 沸点：
  366.7±27.0 °C(Predicted)
• 密度：
  1.439±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-bromophenyl)-3-hydroxypropanoate 在 potassium phosphate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 lithium hydroxide monohydrate 、 偶氮二甲酸二异丙酯 、 XPhos Pd G2 、 potassium acetate 、 N,N-二异丙基乙胺 、 三苯基膦 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 84.0h， 生成 ethyl (3S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)phenyl)azetidin-1-yl)propanoate
  参考文献：
  名称：

  [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
  [FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V

  摘要：

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。

  公开号：

  WO2018089355A1
• 作为产物：
  描述：

  3-hydroxy-2-(4-bromophenyl)acrylic acid ethyl ester 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 8.0h， 以79%的产率得到ethyl 2-(4-bromophenyl)-3-hydroxypropanoate
  参考文献：
  名称：

  脂肪酶PS分离动力学分离乙酸乙酯及其衍生物。

  摘要：

  报道了使用脂肪酶PS和乙酸乙烯酯作为酰化剂的第一动力学分解动力学。生成的（S）-（-）-3-乙酰氧基丙酸乙酯和（R）-（+）-丙酸乙酯以高收率和优良的ee（87-94％）产生。该方法已扩展为可解决各种对苯二甲酸酯衍生物的方法。此外，使用NaBH 4从3-羟基-2-苯基丙烯酸乙酯制备三氟乙酸乙酯及其衍生物的外消旋混合物的改进方法甲醇中有报道。此过程比以前的过程更好，因为它更清洁，更安全且易于处理。还报道了一种使用HCl / CH 3 OH使手性3-乙酰氧基丙酸乙酯脱酰基的改进方法，而没有任何立体化学完整性的损失。

  DOI：

  10.1016/j.tetasy.2004.08.013

文献信息

• Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11014922B2

  公开（公告）日：2021-05-25

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）化合物：或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物是含αv整合素的拮抗剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与含av整合素失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Differential analgesic activity of the enantiomers of atropine derivatives does not correlate with their muscarinic subtype selectivity
  作者：S Dei、A Bartolini、C Bellucci、C Ghelardini、F Gualtieri、D Manetti、M.N. Romanelli、S Scapecchi、E Teodori

  DOI：10.1016/s0223-5234(97)83285-0

  日期：1997.7

  The enantiomers of several tropic and p-substituted tropic acid esters related to atropine obtained by esterification under non-racemizing conditions after resolution of the corresponding racemic acids [(+)- and (-)-18, (+)- and (-)-19] are reported. They were tested in vitro on muscarinic subtype receptors and in vivo for their analgesic activity on mice. As in the case of the lead compound, R-(+)-hyoscyamine, these substances show enantioselectivity in analgesic tests, the eutomers being the R-(+) or R-(+)-p-substituted tropic acid derivatives. However, this property, which is a consequence of increased central release of ACh, seems unrelated to muscarinic subtype selectivity insofar as the compounds are unable to discriminate muscarinic subtype receptors. A possible explanation of these results which does not involve subtype selectivity is proposed, based on the recently developed concept of inverse agonism.
• CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3538526A1

  公开（公告）日：2019-09-18
• CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210246136A1

  公开（公告）日：2021-08-12

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α v -containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
• [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089355A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。